Compound class:
Synthetic organic
Comment: Compound 41 is a structurally novel, potent, selective and orally bioavailable PI3Kδ inhibitor [1]. Results from this inhibitor optimisation study suggest that off-target inhibition of Vps34 is associated with in vivo toxicity in a rat PK model.
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
Immunopharmacology Comments |
Given the leukocyte-restricted expression of PI3Kδ this kinase has been targeted for the development of anti-inflammatory pharmaceuticals for the treatment of respiratory diseases, chronic obstructive pulmonary disease, autoimmune disorders and chronic inflammatory diseases. Isoform selectivity is an important element of drug development, to prevent off-target side-effects at the ubiquitously expressed α and β isoforms, particularly with respect to the long-term treatment required for chronic diseases. |